Stephen Deal, MD
Gastroenterology · Charlotte, NCNPI 1598783961
Payments from drug & device makers
Across 449 payments — averaging $2104.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Wilson Cook Medical Incorporated$929K
- Cook Incorporated$9K
- AbbVie$2K
- Vivus LLC$553
- Pfizer$541
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$480
- plus $3K from 29 others
What the payments were for
- Royalty or licence$937,83899%
- Food & beverage$7,0661%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Wilson Cook Medical Incorporated | 27 | $929,204 |
| Cook Incorporated | 1 | $8,634 |
| AbbVie(2 entities) | 125 | $2,107 |
| Vivus LLC | 37 | $553 |
| Pfizer | 34 | $541 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $480 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $436 |
| Bristol Myers Squibb | 33 | $428 |
| Johnson & Johnson | 21 | $375 |
| Ironwood Pharmaceuticals, Inc | 24 | $363 |
| QOL Medical, LLC | 22 | $319 |
| Redhill Biopharma Inc. | 9 | $147 |
| 3-d Matrix, Inc. | 1 | $144 |
| Ferring Pharmaceuticals Inc. | 9 | $138 |
| Amgen | 6 | $129 |
| Sanofi | 6 | $106 |
| Intercept Pharmaceuticals, Inc. | 5 | $90 |
| Nestle Healthcare Nutrition Inc. | 4 | $90 |
| Intra-sana Laboratories | 2 | $85 |
| Cook Medical LLC | 2 | $72 |
| Gilead | 3 | $62 |
| Alnylam Pharmaceuticals Inc. | 3 | $54 |
| Regeneron Healthcare Solutions, Inc. | 3 | $52 |
| Braintree Laboratories, Inc. | 3 | $49 |
| Lilly USA, LLC | 2 | $44 |
| W. L. Gore & Associates, Inc. | 2 | $31 |
| Boehringer Ingelheim | 2 | $29 |
| Organon | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Fresenius Kabi USA, LLC | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Evoke Pharma, Inc. | 1 | $16 |
| Merck | 1 | $14 |
| Conmed Corporation | 1 | $13 |
| Shionogi Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cook Medical Biliary$321,034
- Fusion Quattro$319,168
- FUSION$289,002
How this compares
$944,904 in reported general payments places this provider in the 95th percentile of 610 gastroenterology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 105 | $351,324 |
| Humira(Cf) PenAdalimumab | 21 | $224,538 |
| LinzessLinaclotide | 106 | $99,350 |
| ZenpepLipase/Protease/Amylase | 20 | $83,806 |
| Dexlansoprazole DrDexlansoprazole | 63 | $21,213 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 316 | $21,026 |
| Balsalazide Disodium | 53 | $16,627 |
| Mesalamine | 24 | $16,617 |
| Mesalamine DrMesalamine | 13 | $9,062 |
| Pantoprazole Sodium | 731 | $7,773 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 34 | $5,842 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 35 | $5,736 |
| Budesonide DrBudesonide | 51 | $5,428 |
| Mesalamine ErMesalamine | 22 | $4,894 |
| MovantikNaloxegol Oxalate | 11 | $4,354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $2,107 | $450,674211 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $138 | $5,84234 claims |
| Braintree Laboratories, Inc.Sutab | $49 | $5,73635 claims |
| Redhill Biopharma Inc.Movantik | $147 | $4,35411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 610 gastroenterology providers in North Carolina.
Other gastroenterology in Charlotte
- Fred FowlerCharlotte$1.2M
- Nilesh LodhiaCharlotte$1.2M
- John HansonCharlotte$885K
- David SmithCharlotte$489K
- Ronnie CyznerCharlotte$481K
- Jason WilsonCharlotte$464K
- Christopher FerrisCharlotte$352K
- Sanjib MohantyCharlotte$302K
- John RoddeyCharlotte$240K
- Baharak MoshireeCharlotte$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.